Publication
Wild mushrooms for Alzheimer’s disease
| dc.contributor.author | Silva, Margarida Lobo | |
| dc.contributor.author | Reis, Filipa S. | |
| dc.contributor.author | Grosso, Clara | |
| dc.contributor.author | Pérez, Diana Valverde | |
| dc.contributor.author | Barros, Lillian | |
| dc.contributor.author | Martins, Rosário | |
| dc.date.accessioned | 2024-06-07T08:36:53Z | |
| dc.date.available | 2024-06-07T08:36:53Z | |
| dc.date.issued | 2023-10-21 | |
| dc.description.abstract | Alzheimer’s disease (AD) is among the most incident, debilitating, and widespread forms of dementia. AD causes the decline of cognitive function, making overall day-to-day tasks difficult and even impossible. Despite extensive research, its origin and progression are still unclear, and no efficient treatment is available to prevent disease progression or mitigate symptoms. Due to the low efficiency in the available treatments, natural compounds have arisen as an alternative. These are gaining crescent relevance and have been explored, given their promising results as immunomodulatory, anti-inflammatory, or neuroprotective factors. Mountain natural resources, specifically mushrooms, are among the most studied sources of bioactive molecules. The Montesinho Natural Park, located in northeast Portugal, has incredible mushroom biodiversity, which has been exploited to obtain health-beneficial compounds, namely with anti-inflammatory potential. This work aimed to study different mushroom extracts and isolated compounds for the prevention and progression of AD. So far, our work aimed at bringing insight into the effect of extract administration in neuroblastoma and endothelial cell lines through the MTT viability assay, as well as studying their effects on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), enzymes known to be involved in AD pathogenesis through a modified Ellman’s method: dry extracts were resuspended in tris-HCl 50mM + 10% DMSO to concentrations between 2 and 0.03125 mg/mL for enzymatic inhibition assays. To be considered promising, extracts must not cause cellular death of over 15-20% and cause enzymatic inhibition. So far, our results using nine mushroom extracts show low-to-no cytotoxicity in concentrations between 100 and 6.25 µg/mL in endothelial and neuroblastoma cell lines. High concentrations of Lycoperdon umbrinum extract caused cytotoxicity levels of approximately 35% in endothelial cells after 24h treatment; different extracts caused cell proliferation in both cell lines, the most evident being 128% in the lowest concentrations of Russula delica and Boletus fragrans. The most promising results were obtained for Boletus aereus, which, while not cytotoxic, inhibited both enzymes by 60%. Around 30% AChE inhibition was achieved for the two highest concentrations of Agaricus silvicola and Boletus fragrans making both extracts good candidates for further studies. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Lobo-Silva, M., Reis, F. S., Grosso, C., Pérez, D. V., Barros, L., & Martins, R. (2022). Wild mushrooms for Alzheimer’s disease. Book of Abstracts of 5th Meeting of Medicinal Biotechnology (5MBtM) and 2nd Iberian Congress on Medicinal Biotechnology, 25. https://paginas.ess.ipp.pt/ebtm/2022/5EBTM_BookOfAbstracts.pdf | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.22/25631 | |
| dc.language.iso | eng | pt_PT |
| dc.publisher | Escola Superior de Saúde P.Porto | pt_PT |
| dc.relation | The authors are grateful to the Foundation for Science and Technology (FCT, Portugal) for financial support through national funds FCT/MCTES (PIDDAC) to CIMO (UIDB/00690/2020 and UIDP/00690/2020) and SusTEC (LA/P/0007/2021); and to the national funding by FCT, P.I., through the institutional scientific employment program-contract for L. Barros’ contract. F.S. Reis thanks FCT for her employment program–contract (2021.03728. CEECIND). Further acknowledgments are due to the European Regional Development Fund (ERDF) through the Regional Operational Program North 2020, within the scope of Project GreenHealth (Norte-01-0145-FEDER-000042). | pt_PT |
| dc.relation.publisherversion | https://paginas.ess.ipp.pt/ebtm/2022/5EBTM_BookOfAbstracts.pdf | pt_PT |
| dc.subject | Alzheimer’s disease | pt_PT |
| dc.subject | Neurodegenerative disease | pt_PT |
| dc.subject | Natural products | pt_PT |
| dc.subject | Bioactive compounds | pt_PT |
| dc.title | Wild mushrooms for Alzheimer’s disease | pt_PT |
| dc.type | conference object | |
| dspace.entity.type | Publication | |
| oaire.citation.conferencePlace | Porto | pt_PT |
| oaire.citation.startPage | 25 | pt_PT |
| oaire.citation.title | Book of Abstracts of 5th Meeting of Medicinal Biotechnology (5MBtM) and 2nd Iberian Congress on Medicinal Biotechnology | pt_PT |
| person.familyName | Silva | |
| person.familyName | Martins | |
| person.givenName | Ana Margarida | |
| person.givenName | Rosario | |
| person.identifier.ciencia-id | 9712-AF1E-C8D1 | |
| person.identifier.ciencia-id | A919-DB40-EF10 | |
| person.identifier.orcid | 0000-0002-9582-3178 | |
| person.identifier.orcid | 0000-0002-9882-4651 | |
| person.identifier.scopus-author-id | 21834368700 | |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | conferenceObject | pt_PT |
| relation.isAuthorOfPublication | 76fafad5-3c94-44d5-bc2a-9814e0ecb940 | |
| relation.isAuthorOfPublication | 82a7c349-c88e-450f-adc7-3331d69149cf | |
| relation.isAuthorOfPublication.latestForDiscovery | 82a7c349-c88e-450f-adc7-3331d69149cf |